# Heinz Wiendl

Heinz Wiendl (born 1968 in Rötz) is a German neurologist and professor at the University Hospital Freiburg. He is known for his works in the field of nervous system inflammation and multiple sclerosis.

## Biography

Wiendl studied psychology and medicine from 1989 to 1996 at the University of Erlangen-Nuremberg, Germany, Duke University, North Carolina, and Bale University, Switzerland. He obtained his MD in 1996. In the following years, he was a scholar of the German Research Council (Deutsche Forschungsgemeinschaft) at the Max Planck Institute of Neurobiology (Martinsried), worked as a clinical and research fellow at the Department of Neurology Tuebingen, received board certification (2004) and completed his habilitation (2004). In 2005 he was appointed as a professor of neurology and head of the clinical research group for MS and neuroimmunology in Wuerzburg and acted as a vice-chair of the Department of Neurology. In 2010 he was recruited to the University of Muenster, where he accepted the position as a director of the Department of Neurology – Inflammatory Diseases of the Nervous System and Neurooncology. From 2013-2024, Prof. Wiendl served as head of the Department of Neurology, Muenster – to which the Institute of Translational Neurology has been associated since 2018. His research focuses on inflammatory neurodegeneration and immune regulation and protection as well as monitoring MS and its therapy. In October 2024, Prof. Wiendl was recruited as Director of the Department of Neurology and Neurophysiology at Freiburg University.

## Scientific contribution

Wiendl’s clinical and scientific work focusses on inflammatory diseases of the nervous system. Taking multiple sclerosis as an exemplary disease, he primarily investigates aspects of immunoregulation and the interaction between immune system and nervous system. Furthermore, Wiendl conducted research projects on immune cell trafficking and explores biomarkers for the prognosis and therapy of multiple sclerosis. By establishing translational research projects, his work helps to further elucidate the question of how immune therapies in neurological diseases work and how new mechanisms of action can be developed. In his research projects, Wiendl pursues a translational approach, closely connecting laboratory work with patient care. With this objective, he also established a biobank at the Department of Neurology Muenster. Wiendl was involved in the development of the monoclonal antibody daclizumab which was approved in 2016 and exhibits a completely new mechanism of action in MS therapy, and Ofatumumab. Heinz Wiendl helped to establish the multiple sclerosis network KKNMS (Krankheitsbezogenes Kompetenznetzwerk Multiple Sklerose). He was co-speaker of the transregional collaborative research center 128 ("Multiple Sclerosis") of the DFG and as a member of the steering committee of the excellence cluster "Cells in Motion" (CiM), funded by the German federal government. In 2019, Wiendl was one of the main initiators of the successful application for funds from the German government to build the "Body and Brain Institute" and acted as speaker of the project until 2024.

## Academic memberships

Wiendl is a member in the following academic societies: German Society for Immunology (DGfI), German Society of Multiple Sclerosis (DMSG), German Society for Muscular Disease (DGM), German Society of Neurology (DGN), American Academy of Neurology (AAN), International Society of Neuroimmunology (ISNI), Editorial Board of the Public Library of Science (PLoS) ONE.

## Honors and awards

* 2017 Honorary professor at Sydney medical school
* 2015 Sobek award for MS research of the German Society of Multiple Sclerosis (DMSG)
* Heinrich-Pette award of the German Society for Neurology (DGN)
* 2004 Sobek award for MS research (young scientists’ award) of the German Society of Multiple Sclerosis (DMSG)
* 2003 Felix-Jerusalem award of the German Society for Muscular Disease (DGM)

## Third-party funding

Wiendl receives funds from the European Union, the federal ministry for education and research (BMBF) for Germany and Nordrhein-Westfalen, the Deutsche Forschungsgesellschaft (DFG), the program for innovative medical research (IMF) of the medical faculty Muenster, the interdisciplinary center for clinical research (IZKF) Muenster, the Else-Kroener-Fresenius-Stiftung and the RE Children’s Foundation.

## Publications

Wiendl published more than 750 scientific works and reviews, books, book chapters and monographies (as of January 2025). Selected publications:
* Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 23(11):1119-1132.
* Schneider-Hohendorf T, Wünsch C, Falk S, Raposo C, Rubelt F, Mirebrahim H, Asgharian H, Schlecht U, Mattox D, Zhou W, Dawin E, Pawlitzki M, Lauks S, Jarius S, Wildemann B, Havla J, Kümpfel T, Schrot MC, Ringelstein M, Kraemer M, Schwake C, Schmitter T, Ayzenberg I, Fischer K, Meuth SG, Aktas O, Hümmert MW, Kretschmer JR, Trebst C, Kleffner I, Massey J, Muraro PA, Chen-Harris H, Gross CC, Klotz L, Wiendl H*, Schwab N*. Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation. Brain. doi: 10.1093/brain/awae244. (Epub 2024 Jul 18) (equal contribution)
* Gross CC* Schulte-Mecklenbeck A*, Steinberg OV*, Wirth T*, Lauks S*, Bittner S*, Schindler P, Baranzini SE, Groppa S, Bellmann-Strobl J, Bünger N, Chien C, Dawin E, Eveslage M, Fleischer V, Gonzalez-Escamilla G, Gisevius B, Haas J, Kerschensteiner M, Kirstein L, Korsukewitz C, Lohmann L, Lünemann JD, Luessi F, Meyer zu Hörste G, Motte J, Ruck T, Ruprecht K, Schwab N, Steffen F, Meuth SG, Paul F, Wildemann B, Kümpfel T, Gold R, Hahn T, Zipp F, Klotz L*, Wiendl H*, KKNMS (2024) Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories. Sci Transl Med. 6(740):eade8560. (*shared first/last authorship)
* Ostkamp P, Deffner M, Schulte-Mecklenbeck A, Wünsch C, Lu IN, Wu GF, Goelz S, De Jager PL, Kuhlmann T, Gross CC, Klotz L, Meyer Zu Hörste G, Wiendl H*, Schneider-Hohendorf T*, Schwab N* (2022) A single-cell analysis framework allows for characterization of CSF leukocytes and their tissue of origin in multiple sclerosis. Sci Transl Med. 14(673):eadc9778.
* Schneider-Hohendorf T*, Gerdes LA*, Pignolet B*, Gittelman R, Ostkamp P, Rubelt F, Raposo C, Tackenberg B, Riepenhausen M, Janoschka C, Wünsch C, Bucciarelli F, Flierl-Hecht A, Beltrán E, Kümpfel T, Anslinger K, Gross CC, Chapman H, Kaplan I, Brassat D, Wekerle H, Kerschensteiner M, Klotz L, Lünemann JD, Hohlfeld R, Liblau R*, Wiendl H*, Schwab N*(2022) Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis. J Exp Med. 219(11):e20220650.
* Räuber S, Heming M, Repple J, Ruland T, Kuelby R, Schulte-Mecklenbeck A, Gross CC, Arolt V, Baune B, Hahn T, Dannlowski U, Meuth SG, Melzer N, Wiendl H, Meyer Zu Hörste G. (2021) Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses. Mol Psychiatry 26(12):7661-7670.
* Gross CC*, Schulte-Mecklenbeck A*, Madireddy L, Pawlitzki M, Strippel C, Räuber S, Krämer J, Rolfes L, Ruck T, Beuker C, Schmidt-Pogoda A, Lohmann L, Schneider-Hohendorf T, Hahn T, Schwab N, Minnerup J, Melzer N*, Klotz L, Meuth SG*, Meyer Zu Hörste G, Baranzini SE, Wiendl H. (2021) Classification of neurological diseases using multi-dimensional CSF analysis. Brain 144(9):2625-2634.
* Ostkamp P, Salmen A, Pignolet B, Görlich D, Andlauer TFM, Schulte-Mecklenbeck A, Gonzalez-Escamilla G, Bucciarelli F, Gennero I, Breuer J, Antony G, Schneider-Hohendorf T, Mykicki N, Bayas A, Then Bergh F, Bittner S, Hartung HP, Friese MA, Linker RA, Luessi F, Lehmann-Horn K, Mühlau M, Paul F, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber F, Wildemann B, Zettl UK, Ziemann U, Müller-Myhsok B, Kümpfel T, Klotz L, Meuth SG, Zipp F, Hemmer B, Hohlfeld R, Brassat D, Gold R, Gross CC, Lukas C, Groppa S, Loser K, Wiendl H*, Schwab N*; German Competence Network Multiple Sclerosis (KKNMS) and the BIONAT Network. (2021) Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proc Natl Acad Sci U S A 118(1):e2018457118.
* Heming M, Li X, Räuber S, Mausberg AK, Börsch AL, Hartlehnert M, Singhal A, Lu IN, Fleischer M, Szepanowski F, Witzke O, Brenner T, Dittmer U, Yosef N, Kleinschnitz C, Wiendl H, Stettner M, Meyer Zu Hörste G. (2021) Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. Immunity 54(1):164-175.e6.
* Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. (2020) Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 6;383(6):546-557.
* Gerdes LA*, Janoschka C*, Eveslage M, Mannig B, Wirth T, Schulte-Mecklenbeck A, Lauks S, Glau L, Gross CC, Tolosa E, Flierl-Hecht A, Ertl-Wagner B, Barkhof F, Meuth SG, Kümpfel T, Wiendl H*, Hohlfeld R*, Klotz L*. (2020) Immune signatures of prodromal multiple sclerosis in monozygotic twins. Proc Natl Acad Sci U S A 117(35):21546-21556. (*contributed equally)
* Schafflick D, Xu CA, Hartlehnert M, Cole M, Schulte-Mecklenbeck A, Lautwein T, Wolbert J, Heming M, Meuth SG, Kuhlmann T, Gross CC, Wiendl H, Yosef N, Meyer Zu Horste G (2020) Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat Commun 11(1):247.
* Klotz L*, Eschborn M*, Lindner M*, Liebmann M, Herold M, Janoschka C, Torres Garrido B, Schulte-Mecklenbeck A, Gross CC, Breuer J, Hundehege P, Posevitz V, Pignolet B, Nebel G, Glander S, Freise N, Austermann J, Wirth T, Campbell GR, Schneider-Hohendorf T, Eveslage M, Brassat D, Schwab N, Loser K, Roth J, Busch KB, Stoll M, Mahad DJ, Meuth SG, Turner T, Bar-Or A, Wiendl H. (2019) Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Sci Transl Med. 11(490). pii: eaao5563.
* H. Wiendl Publication list ResearchGate
* H. Wiendl Publication list PubMed